Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy.
Liu, C.C., Kanekiyo, T., Xu, H., and Bu, G. (2013). Nat. Rev. Neurol. 9, 106–118.
Apolipoprotein E sets the stage: response to injury triggers neuropathology.
Mahley, R.W., Huang, Y. (2012). Neuron 76, 871-885.
Roles of apolipoprotein E in Alzheimer’s Disease and other neurological disorders.
Verghese, P.B., Castellano, J.M., and Holtzman, D.M. (2011). Lancet Neurol. 10, 241–252.
Longitudinal modeling of age-related memory decline and the ApoE Ɛ4 effect.
Caselli, R.J., Dueck, A. C., Osborne, D., Sabbagh, M.N., Connor, D.J., Ahern, G.L., Baxter, L.C., Rapcsack,
S.Z., Shi, J., Woodruff, B.K., et al. (2009). N. Engl. J. Med. 361, 255-263.
ApoE genotype accounts for the vast majority of AD risk and AD pathology.
Raber, J., Huang, Y., Ashford, J.W. (2004). Neurobiol. Aging 25, 641-650.